地洛他定治疗过敏性鼻炎114例的临床疗效和安全性评价

目的 :评价地洛他定治疗过敏性鼻炎的临床疗效和安全性。方法 :采用多中心、随机、双盲、阳性药物平行对照研究。入选过敏性鼻炎病人 2 4 0例 ,完成 2 2 4例 ,其中地洛他定组 114例 ,男性 5 5例 ,女性 5 9例 ,年龄 (4 0±s 7)a ,病程 (6 6± 9)mo ,服用地洛他定 ,5mg,po ,qd ;氯雷他定组 110例 ,男性 4 5例 ,女性 6 5例 ,年龄 (39± 7)a ,病程 (6 3± 8)mo ,予氯雷他定 ,10mg,po ,qd。 2组疗程均为2wk ,观察 2组疗效和不良反应。结果 :地洛他定用于治疗过敏性鼻炎 2wk后的显效例数和有效率分别为 4 6例和 92 .1% ,氯雷他定组的显效例数和有效率分别为 32例和 88.2 %。 2组疗效差异无显著意义 (P >0 .0 5 )。 2组均未出现严重及预料之外的不良反应 ,地洛他定组和氯雷他定组的不良反应发生率分别为 8.3%和 15 .0 % ,P >0 .0 5。结论 :地洛他定治疗过敏性鼻炎具有明显疗效 ,不良反应轻微

Evaluation of clinical effect and safety of desloratadine in treating allergic rhinitis

AIM: To evaluate the effect and safety of delortadine in treating allergic rhinitis. METHODS: A multi-center randomized and double-blind clinical trial was used. Two hundred and forty patients were divided into two groups and 224 patients finished the trial in the end. The desloratadine group of 114 patients (M 55,F 59;age(40±s 7) a) took desloratadine tablet (5 mg),po,qd. The loratadinum group of 110 patients (M 45,F 65;age(39±7) a ) took loratadinum tablet 10 mg,po,qd. The period of treatment of both groups was 2 wk. RESULTS: After 2 wk treatment, the notable effective patients and the effective rate of desloratadine were 46 and (92.1 %), those of loratadine were 32 and (88.2 %). There was no difference between two groups (P>(0.05)). The adverse reaction rate was (8.3 %) and (15.0 %), respectively. There was no signficant difference between two groups (P>(0.05)). CONCLUSION: Desloratadine in treating allergic rhinitis is safe and effective with mild adverse reactions.